CLVS
$6.84
Clovis Oncology
($.64)
(8.56%)
CLVS
Earnings Whisper ®
N/A
1st Quarter March 2020
Consensus:  ($1.27)
Revenue:  N/A
Monday
May 25
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Monday, February 24, 2020

What do you expect when CLVS reports earnings?
Beat
Meet
Miss

Where is CLVS's stock price going from here?
Up
Flat
Down
Stock chart of CLVS
Analysts
Summary of analysts' recommendations for CLVS
Score
Grade
Pivots
Resistance
$9.28
$8.84
$8.16

$7.73

Support
$7.04
$6.61
$5.93
Tweet
Growth
Description
Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsInterCeptZoetisJohnson & JohnsonMylanUltragenyx PharmaceuticalEndo International plcBristol-Myers Squibb